Astrazeneca Plc · LSE:AZN
Astrazeneca — ASCO Investor Event 2025
49 slides from Astrazeneca's conference presentation, Jun 2, 2025
Slide 1: Meet AZN Management: ASCO Investor Event
Meet AZN Management: ASCO Investor Event 2 June 2025
Slide 2: Forward-looking statements
Forward-looking statements This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures.
Slide 3: AstraZeneca @ ASCO 2025
AstraZeneca @ ASCO 2025 Furthering the AstraZeneca ambition Pascal Soriot, Chief Executive Officer Key Oncology themes at ASCO Susan Galbraith, EVP, Oncology Haematology R&D Redefining the breast cancer landscape Prof. Nick Turner, Consultant Medical Oncologist, Royal Marsden • SERENA-6 Dr Sara Tola
Slide 4: Furthering the AstraZeneca ambition
Furthering the AstraZeneca ambition Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth
Ambition – $80bn Total Revenue by 2030 & sustained 2030+ growth Beyond 2030 Working on “today, tomorrow and the day after" ADCs and Radioconjugates Illustrative only, not to scale Cell therapy and T-cell engagers Launching key NMEs $80bn Gene therapy AZD0120 saruparib AZD0486 volrustomig Next-genera
Slide 6: Pipeline advancing at pace and significant progress with transformative technologies
Pipeline advancing at pace and significant progress with transformative technologies Weight management ADCs and Cell therapy and Gene therapy and Next-gen IO bispecifics and risk factors Radioconjugates T-cell engagers gene editing Establish and lead Develop scalable cell Replace systemic Make cure
Slide 7: Unprecedented catalyst rich period with key Phase III readouts in 2025 and 2026
Unprecedented catalyst rich period with key Phase III readouts in 2025 and 2026 CALYPSO | eneboparatide AVANZAR | Datroway + Imfinzi TROPION-Lung07 | Datroway OBERON/TITANIA | tozorakimab 2026 H2 2025 H1 2025 hypoparathyroidism 1L NSQ/NSQ TROP2+ NSCLC 1L NSQ NSCLC COPD DESTINY-Breast09 | Enhertu DES
Slide 8: A growing broad-based global footprint
A growing broad-based global footprint Resilient, dual-source supply chain with strategic investments in new technologies and R&D Cambridge, UK Gothenburg, Sweden Gaithersburg, US Boston, US – Kendall Sq. Strategic R&D centre Legend Existing site New site Increasing investment Shanghai, China Beiji
Slide 9: Remarkable series of ASCO plenaries since 2020
Remarkable series of ASCO plenaries since 2020 8 5 3 2 1 1 1 1 1 1 1 1 1 9 Count of plenary sessions by pharmaceutical company since 2020 based on trial active arm. Appendix: Glossary.
Slide 10: Key Oncology themes at ASCO
Key Oncology themes at ASCO Susan Galbraith EVP, ONCOLOGY HAEMATOLOGY R&D
Slide 11: Focused strategy to redefine cancer care
Focused strategy to redefine cancer care Novel ADCs and Replace the backbone of chemotherapy 7 consecutive years of ASCO plenaries Radioconjugates 1 and radiotherapy POLO ADAURA OlympiA Next wave of IO agents will segment Novel IO 2 the IO-sensitive space Cell therapy and Scalable, accessible therap
Slide 12: Eight simultaneous publications during ASCO, including three in NEJM
• SERENA-6 Plenary US BTD • DESTINY-Breast09 Special session 82 abstracts accepted • MATTERHORN Plenary 43 poster presentations • DESTINY-Gastric04 • GEMINI-HPB 19 oral presentations • NeoADAURA 2 plenary presentations • TROPION-Lung02 1 special LBA session • TROPION-Lung04 • NeoCOAST-2 • SACHI, SAV
Slide 13: AstraZeneca ground-breaking data across tumour types
AstraZeneca ground-breaking data across tumour types Establishing a new endocrine Moving Enhertu earlier in HER2+ mBC backbone with camizestrant Redefining care in DESTINY-Breast09 SERENA-6 breast cancer Phase III Enhertu + pertuzumab Phase III switch to cami with CDK4/6i in 1L HER2+ mBC in 1L ESR1m
Slide 14: Leading development programme in lung cancer
Leading development programme in lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1L 2L 3L+ Est. epi (G7, 2025) ~150K ~70K ~50K ~100K ~310K ~190K ~70K Imfinzi CRT → Imfinzi Imfinzi + Imjudo + CTx POSEIDON AEGEAN PACIFIC Datroway + IO ± platinum TL08/TL07/AVANZAR I
Slide 15: NeoADAURA: Reinforces ADAURA and LAURA with Tagrisso in curative settings
NeoADAURA: Reinforces ADAURA and LAURA with Tagrisso as a backbone in curative settings for EGFRm NSCLC Significant improvement in MPR rate1 Favourable EFS trend2 Difference 24% (95% CI 15-32) OR 19.8 (95.002% CI 4.6-85.3); p<0.0001 Difference 23% (95% CI 15-32) OR 19.3 (99.9% CI 1.7-217.4); p<0.000
Slide 16: Potential for Datroway + IO to transform treatment expectations in NSCLC
Potential for Datroway + IO to transform treatment expectations in advanced and early-stage NSCLC pCR and MPR doubled with Trend to PFS and OS benefit with Ability to combine Datroway triplet vs SoC AEGEAN TROP2 NMR biomarker in 1L NSCLC with next generation IO Phase II NeoCOAST-2 Phase Ib TROPION-L
Slide 17: Leading development programme in breast cancer
Leading development programme in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu + THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Breast11 DESTINY-Breas
Slide 18: SERENA-6
SERENA-6 Prof. Nicolas Turner CONSULTANT MEDICAL ONCOLOGIST, ROYAL MARSDEN
Slide 19: SERENA-6: Innovative trial design leveraging ctDNA to inform treatment switch
SERENA-6: Innovative trial design leveraging ctDNA to inform treatment switch in 1L HR+ advanced BC camizestrant + continuing CDK4/6i + Primary endpoint: ― ER+ HER2- advanced breast placebo for AI PFS by investigator assessment cancer (aBC)1 (RECIST v1.1) ― ≥6 months of AI + CDK4/6i Stratification f
Slide 20: SERENA-6: Camizestrant + CDK4/6i reduced risk of progression or death by 56%
SERENA-6: Camizestrant + CDK4/6i reduced the risk of progression or death by 56% camizestrant + AI + CDK4/6i CDK4/6i (N=157) (N=158) PFS events 71 100 100 mPFS (95% CI), mo 16.0 (12.7–18.2) 9.2 (7.2–9.5) 90 Adjusted HR (95% CI) 0.44 (0.31–0.60) P<0.00001 Progression-free survival (%) 80 70 60.7% 60
Slide 21: SERENA-6: Consistent benefit across subgroups
SERENA-6: Consistent benefit across subgroups for camizestrant + CDK4/6i camizestrant + AI + Subgroup CDK4/6i CDK4/6i Hazard ratio (95% CI) # of events/total All patients 71/157 100/158 0.44 (0.31–0.60) <65 years 44/95 67/104 0.51 (0.34–0.74) Age ≥65 years 27/62 33/54 0.35 (0.21–0.59) Asian 22/39 25
Slide 22: SERENA-6: Reduced risk of deterioration of HRQoL
SERENA-6: Camizestrant + CDK4/6i reduced the risk of deterioration of HRQoL camizestrant + AI + CDK4/6i CDK4/6i (N=107) (N=95) Events 36 49 100 Median time to deterioration (95% CI), mo 23.0 (13.8–NC) 6.4 (2.8, 14.0) 90 Deterioration-free survival (%) Adjusted HR (95% CI) 0.53 (0.33–0.82) 80 Nominal
Slide 23: SERENA-6: Consistent benefit in second progression-free survival
SERENA-6: Consistent benefit in second progression-free survival (PFS2) camizestrant + AI + CDK4/6i CDK4/6i (N=157) (N=158) 100 PFS2 events 38 47 85.4% Adjusted HR (95% CI) 0.52 (0.33–0.81) Second progression-free survival (%) 90 P=0.0038 [interim analysis threshold p=0.0001] 80 Information fraction
Slide 24: SERENA-6: Well-tolerated with very low discontinuation rate
SERENA-6: Camizestrant + CDK4/6i is well-tolerated with a very low discontinuation rate (<1.5%) Very low discontinuation rates Compelling AE profile camizestrant + CDK4/6i AI + CDK4/6i camizestrant + AI + CDK4/6i (N=155) (N=155) n (%) CDK4/6i (N=155) (N=155) Any adverse event 145 (93.5) 135 (87.1) A
Slide 25: SERENA-6: Camizestrant first next generation oral SERD to demonstrate benefit
SERENA-6: Camizestrant first next generation oral SERD to demonstrate benefit in 1L HR+ advanced BC ― Switching AI to camizestrant with continuation of CDK4/6i, guided by the emergence of ESR1m during 1L therapy ahead of disease progression, significantly improved PFS in patients with HR+/HER2- aBC
Slide 26: DESTINY-Breast09
DESTINY-Breast09 Dr Sara Tolaney CHIEF OF THE DIVISION OF BREAST ONCOLOGY, DANA- FARBER CANCER INSTITUTE
Slide 27: DESTINY-Breast09: Moving Enhertu into 1L to displace THP
DESTINY-Breast09: Moving Enhertu into 1L with potential to displace established standard of care THP ― HER2+ a/mBC Primary endpoint: ― Asymptomatic/inactive brain N = 387 Enhertu2 + placebo mets allowed PFS (BICR) Blinded until final PFS analysis ― DFI >6 mo from last CTx or HER2- Key secondary endp
Slide 28: DESTINY-Breast09: Enhertu + pertuzumab reduced risk of progression by 44%
DESTINY-Breast09: Enhertu + pertuzumab reduced risk of disease progression death by 44% Enhertu + P THP (N=383) (N=387) 40.71 26.9 100 mPFS (95% CI), mo (36.5, NC) (21.8, NC) HR (95% CI) 0.56 (0.44, 0.71) Progression-free survival (%) P<0.000012 80 60 40 20 0 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42
Slide 29: DESTINY-Breast09: Consistent benefit across subgroups
DESTINY-Breast09: Consistent benefit for Enhertu + pertuzumab observed across subgroups No. of events / no. of patients mPFS, months (95% CI) Enhertu + P THP Enhertu + P THP Hazard ratio (95% CI) Prior treatment status De novo 52/200 85/200 NC (36.5, NC) 31.2 (23.5, NC) 0.49 (0.35, 0.70) Recurrent 6
Slide 30: DESTINY-Breast09: High durable response rate and early trend to OS
DESTINY-Breast09: High durable response rate and early trend to OS for Enhertu + pertuzumab ORR1 Overall survival 100 15% 9% Best objective response (BICR) 2 80 Overall survival (%) 60 70% 70% Enhertu + THP 40 pertuzumab (N=387) (N=383) mOS, mo NC NC 20 HR (95% CI) 0.84 (0.59–1.19) ~16% maturity 0 0
Slide 31: DESTINY-Breast09: Safety profile consistent with known profiles
DESTINY-Breast09: Safety profile consistent with known profiles of Enhertu and pertuzumab Lower rate of discontinuations due to AEs Manageable AE profile3 Enhertu + pertuzumab THP (N=381) (N=382) Enhertu + P THP (N=381) (N=382) Total exposure, patient years 659.7 564.0 Any TEAE, n (%) 380 (99.7) 378
Slide 32: DESTINY-Breast09: First improvement in over a decade vs 1L SoC
DESTINY-Breast09: First improvement in over a decade vs current 1L SoC across broad HER2+ mBC population PFS by BICR ― Enhertu + pertuzumab demonstrated a statistically significant and clinically meaningful PFS benefit vs. THP 44% ― mDOR >3 years with Enhertu + pertuzumab, CR in 15.1% vs 8.5% reduct
Slide 33: Realising our ambition in breast cancer
Realising our ambition in breast cancer Sunil Verma SVP, GLOBAL HEAD, ONCOLOGY FRANCHISE
Slide 34: Camizestrant as the new backbone endocrine therapy in HR+ BC
Major progress towards establishing camizestrant as the new backbone endocrine therapy in HR+ BC SERENA-6 | Only oral next generation SERD with Differentiated programme Phase III data in 1L HR+ aBC Broaden camizestrant 85k patients in G7 | 1L HR+ aBC across 1L HR+ aBC SERENA-4 | 2026 50% | currently
Slide 35: Transforming treatment in HER2+ breast cancer
Transforming treatment in HER2+ breast cancer DESTINY-Breast09 | Enhertu + pertuzumab to become a potential 1L SoC for HER2+ mBC Moving into early stage Neoadjuvant approach, ~23k 1L HER2+ mBC patients eligible in G7 high-risk at diagnosis Demonstrated benefit across broad spectrum of 1L HER2+ DESTI
Slide 36: Opportunity for Q&A
Opportunity for Q&A Key External Experts Prof. Nick Turner Dr Sara Tolaney C HI EF O F THE DI VI S I ON O F C O NS ULTA NT MEDI C A L BR EA S T O NC O LO GY, O NC O LOG IS T, R OY AL MA R SD E N DA NA-F AR BE R C AN C ER I NS TI TU TE AstraZeneca Leadership Pascal Soriot Dave Fredrickson EV P, O NC
Slide 37: Expanding leadership in GI cancers
Expanding leadership in GI cancers Cristian Massacesi CHIEF MEDICAL OFFICER & ONCOLOGY CHIEF DEVELOPMENT OFFICER
Slide 38: Building a leading development programme in gastric cancer
Building a leading development programme in gastric cancer Early Advanced/Metastatic Stage II/III 1st line 2nd line 3rd line Est. epi (G7, 2025) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu + pembrol
Slide 39: MATTERHORN: Third positive perioperative trial for Imfinzi
MATTERHORN: Third positive perioperative trial for Imfinzi, building on NIAGARA and AEGEAN success Neoadjuvant Adjuvant (up to 1 year) ― Stage II–IVa gastric and GEJ Primary endpoint: cancer Imfinzi Imfinzi EFS Imfinzi ― No evidence of metastasis + FLOT + FLOT Key secondary ― No prior therapy endpoi
Slide 40: MATTERHORN: Statistically significant EFS benefit for Imfinzi + FLOT
MATTERHORN: Statistically significant EFS benefit for Imfinzi + FLOT Imfinzi + FLOT Placebo + FLOT (n=474)1 (n=474)1 100 mEFS (95% CI), mo NR (40.7–NR) 32.8 (27.9–NR) 90 HR (95% CI) 0.71 (0.58–0.86) P2<0.001 80 73% Median (range) duration 31.6 (0.0–48.1) 31.4 (0.0–48.1) 70 67% of follow-up,3 months
Slide 41: MATTERHORN: Trend to OS benefit with Imfinzi + FLOT
MATTERHORN: Trend to OS benefit with Imfinzi + FLOT Imfinzi + FLOT Placebo + FLOT (n=474)1 (n=474)1 Median OS (95% CI), mo NR (NR–NR) 47.2 (45.1–NR) 100 0.78 (0.62–0.97) HR (95% CI) P2=0.025 90 81% Median (range) duration 34.6 (3.5-48.6) 34.6 (0.0-48.1) 80 76% of follow-up,3 months 70 77% Overall su
Slide 42: MATTERHORN: AE profile consistent with known safety profiles
MATTERHORN: AE profile consistent with known safety profiles of Imfinzi and FLOT AEs did not result in a delay to surgery No new safety signals3 Imfinzi + FLOT (N=475)1 Placebo + FLOT (N=469)1 Imfinzi + FLOT Placebo + FLOT Diarrhoea 62 58 (n=475)1 (n=469)1 Nausea 51 51 Any grade TRAE, % 95 95 Neutro
Slide 43: DESTINY-Gastric04: Phase III data confirm Enhertu benefit in 2L gastric cancer
DESTINY-Gastric04: Phase III data confirm Enhertu benefit in 2L HER2+ metastatic gastric/GEJ cancer Significant survival benefit with Enhertu 100 Enhertu RAM + PTX 83.5% – Enhertu 6.4 mg/kg toxicity mOS, mo 14.7 11.4 80 profile generally manageable HR1 (95% CI) 0.70 (0.55-0.90) P-value 1 = 0.0044 –
Slide 44: GEMINI-HBP: Encouraging efficacy for rilvegostomig + CTx in Phase II
GEMINI-HBP in advanced biliary tract cancer: Encouraging efficacy for rilvegostomig + CTx in Phase II trial Imfinzi has transformed Promising early efficacy for rilvegostomig + CTx2 management of aBTC survival rate at 3 N=29 2x years for Imfinzi + CTx vs CTx alone1 – mPFS 8.3 mo – ORR 31% – mDoR 6.9
Slide 45: Realising our ambition in GI cancers
Realising our ambition in GI cancers Dave Fredrickson EVP, ONCOLOGY HAEMATOLOGY BUSINESS
Slide 46: Building a leading gastrointestinal cancers portfolio
Building a leading gastrointestinal cancers portfolio to transform patient outcomes MATTERHORN | Third perioperative opportunity DESTINY-Gastric04 | Supports for Imfinzi existing Enhertu indications Potential to be first and only perioperative IO-based regimen Already established SoC in 2L+ HER2+ in
Slide 47: Opportunity for Q&A
Opportunity for Q&A AstraZeneca Leadership Pascal Soriot Dave Fredrickson EV P, O NC O LO GY C HI EF EX EC UT IV E O F F I CE R HA EMA TOL OGY BUS I NE SS Susan Galbraith Cristian Massacesi C HI EF M EDI CA L OF F I C ER EV P, O NC O LO GY & O NC O LO GY CHI EF HA EMA TOL OGY R& D DEV ELO PME NT OF
Slide 48: Glossary
Glossary 1L, 2L, 3L first-, second-, third-line GC gastric cancer OS overall survival a/mBC advanced/metatistic breast cancer GEJ gastroesophageal junction P pertuzumab aBC advanced breast cancer GEJA gastroesophageal junction adenocarcinoma PALB2m partner and localizer of BRCA2 aBTC advanced biliar
Slide 49: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis